Paclitaxel-loaded polymeric micelles based on poly(e-caprolactone)-poly(ethylene glycol)-poly(e-caprolactone) triblock copolymers: In vitro and in vivo evaluation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 925-934

  Zhang, Linhua ^a   He, Yingna ^a   Ma, Guilei ^a   Song, Cunxian ^a   Sun, Hongfan ^a  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

Author keywords

Anti tumoral activity; Paclitaxel; PCL PEG PCL; Pharmacokinetics; Polymeric micelles

Indexed keywords

ADVERSE EFFECT; ANTI-CANCER AGENTS; ANTI-TUMORAL ACTIVITY; BREAST TUMOR; BRISTOL-MYERS SQUIBB; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CORE-SHELL MORPHOLOGIES; CYTOTOXIC EFFECTS; DELIVERY METHODS; DRUG-DELIVERY SYSTEMS; ELIMINATION RATE; IN-VITRO; IN-VIVO; INTRAVENOUS INJECTIONS; NANO SCALE; NEW JERSEY; PACLITAXEL; PCL-PEG-PCL; POLY(E-CAPROLACTONE); POLYMERIC MICELLE; POLYMERSOMES; SYSTEMIC CIRCULATION; THERAPEUTIC EFFICACY;

BLOCK COPOLYMERS; CHEMOTHERAPY; CYTOTOXICITY; DISEASES; FUNCTIONAL POLYMERS; MICELLES; PHARMACOKINETICS; POLYETHYLENE OXIDES; TUMORS;

POLYETHYLENE GLYCOLS;

COPOLYMER; CREMOPHOR; MACROGOL; PACLITAXEL; POLY(EPSILON CAPROLACTONE) POLY(ETHYLENE GLYCOL) POLY(EPSILON CAPROLACTONE) COPOLYMER; POLYCAPROLACTONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BREAST TUMOR; CANCER INHIBITION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MICELLE; MICELLIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; RAT; TUMOR CELL; TUMOR GROWTH; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICELLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84864077119     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.11.005     Document Type: Article

References (43)

1. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulation. Int J Pharm 2002, 235:179-192.
2. Spencer C.M., Faulds D. Paclitaxel; a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48:794-847.
3. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990, 8:1263-1268.
4. Akhlaghi S.P., Saremi S., Ostad S.N., Dinarvand R., Atyabi F. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine 2010, 6:689-697.
5. Fan T., Takayama K., Hattori Y., Maitani Y. Formulation optimization of paclitaxel carried by PEGylated emulsions based on artificial neural network. Pharm Res 2004, 21:1692-1697.
6. Huh K.M., Min H.S., Lee S.C., Lee H.J., Kim S., Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release 2008, 126:122-129.
7. Wang X., Zhou J., Wang Y., Zhu Z., Lu Y., Wei Y., et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 2010, 46:1474-1480.
8. Xiao K., Luo J., Fowler W.L., Li Y., Lee J.S., Xing L., et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 2009, 30:6006-6016.
9. Xie Z., Guan H., Chen X., Lu C., Chen L., Hu X., et al. A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release 2007, 117:210-216.
10. Sharma U.S., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci 1995, 84:1223-1230.
11. Elkharraz K., Faisant N., Guse C., Siepmann F., Arica-Yegin B., Oger J.M., et al. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 2006, 314:127-136.
12. Harada Y., Yamamoto T., Sakai M., Saiki T., Kawano K., Maitani Y., et al. Effects of organic solvents on drug incorporation into polymeric carriers and morphological analyses of drug-incorporated polymeric micelles. Int J Pharm 2011, 404:271-280.
13. Kataoka K., Kwon G.S., Yokoyama M., Okano T., Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release 1993, 24:119-132.
14. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., et al. Polymer micelles as novel drugcarrier: Adriamycin-conjugted poly (ethylene glycol)-poly (aspartic acid) block copolymer. J Control Release 1990, 11:269-278.
15. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
16. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
17. Koizumi F., Kitagawa M., Negishi T., Onda T., Matsumoto S., Hamaguchi T., et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 2006, 66:10048-10056.
18. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006, 112:630-648.
19. Miyata K., Christie R.J., Kataoka K. Polymeric micelles for nano-scale drug delivery. React Funct Polym 2011, 71:227-234.
20. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986, 46:6387-6392.
21. Trivedi R., Kompella U.B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) 2010, 5:485-505.
22. Gou M., Zheng L., Peng X., Men K., Zheng X., Zeng S., et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm 2009, 375:170-176.
23. Gong C.Y., Shi S., Dong P.W., Yang B., Qi X.R., Guo G., et al. Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel: part 1-Synthesis, characterization, and acute toxicity evaluation. J Pharm Sci 2009, 98:4684-4694.
24. Wei X., Gong C., Shi S., Fu S., Men K., Zeng S., et al. Self-assembled honokiol-loaded micelles based on poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Int J Pharm 2009, 369:170-175.
25. Letchford K., Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007, 65:259-269.
26. Levine D.H., Ghoroghchian P.P., Freudenberg J., Zhang G., Therien M.J., Greene M.I., et al. Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods 2008, 46:25-32.
27. Cho H., Cheong I., Lee J., Kim J. Polymeric nanoparticles, micelles and polymersomes from amphiphilic block copolymer. Korean J Chem Eng 2010, 27:731-740.
28. Hu Y., Xie J., Tong Y.W., Wang C.H. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 2007, 118:7-17.
29. Lee J., Bae Y.H., Sohn Y.S., Jeong B. Thermogelling aqueous solutions of alternating multiblock copolymers of poly(L-lactic acid) and poly(ethylene glycol). Biomacromol 2006, 7:1729-1734.
30. Zhang X., Jackson J.K., Burt H.M. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 1996, 132:195-206.
31. Ma G., Yang J., Zhang L., Song C. Effective antitumor activity of paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model. Anti-Cancer Drugs 2010, 21:261-269.
32. Howell R.L., Koch C.J. The disaggregation, separation and identification of cells from irradiated and unirradiated EMT6 mouse tumors. Int J Radiat Oncol Biol Phys 1980, 6:311-318.
33. Rockwell S.C., Kallman R.F., Fajardo L.F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 1972, 49:735-749.
34. Janát-Amsbury M.M., Yockman J.W., Lee M., et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004, 9:829-836.
35. Raymond E., Hanauske A., Faivre S., Izbicka E., Clark G., Rowinsky E.K., et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anti-Cancer Drugs 1997, 8:79-385.
36. Kloover J.S., den Bakker M.A., Gelderblom H., van Meerbeeck J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004, 90:304-305.
37. Kim K., Kim J.H., Park H., Kim Y.S., Park K., Nam H., et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010, 146:219-227.
38. Danhier F., Lecouturier N., Vroman B., JérÔme C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133:11-17.
39. Liggins R.T., Burt H.M. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 2002, 54:191-202.
40. Le Garrec D., Ranger M., Leroux J.C. Micelles in anticancer drug delivery. Am J Drug Deliv 2004, 2:15-42.
41. Wei X., Gong C., Gou M., Fu S., Guo Q., Shi S., et al. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm 2009, 381:1-18.
42. Ge H., Hu Y., Jiang X., Cheng D., Yuan Y., Bi H., et al. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(e-caprolactone)-poly(ethylene oxide)-poly(e-caprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci 2002, 91:1463-1473.
43. Remant Bahadur K.C., Bhattarai S.R., Aryal S., Khil M.S., Dharmaraj N., Kim H.Y. Novel amphiphilic triblock copolymer based on PPDO, PCL, and PEG: synthesis, characterization, and aqueous dispersion. Colloids Surf A Physicochem Eng Asp 2007, 292:69-78.